{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:41:33Z","timestamp":1788309693206,"version":"build-2803163510"},"reference-count":49,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100005788","name":"Medizinische Universit\u00e4t Wien","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005788","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Rheumatic Disease Clinics of North America"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.rdc.2019.07.001","type":"journal-article","created":{"date-parts":[[2019,8,16]],"date-time":"2019-08-16T18:03:11Z","timestamp":1565978591000},"page":"477-485","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"title":["Treat to Target in Rheumatology"],"prefix":"10.1016","volume":"45","author":[{"given":"Josef S.","family":"Smolen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.rdc.2019.07.001_bib1","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1001\/jama.1970.03170330025003","article-title":"Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressure averaging 90 through 114\u00a0mm Hg","volume":"213","year":"1970","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.rdc.2019.07.001_bib2","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1001\/archinte.163.6.681","article-title":"Awareness, knowledge, and attitudes of older americans about high blood pressure: implications for health care policy, education, and research","volume":"163","author":"Egan","year":"2003","journal-title":"Arch Intern Med"},{"issue":"19","key":"10.1016\/j.rdc.2019.07.001_bib3","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1056\/NEJM199505113321915","article-title":"Glycosylated hemoglobin and the risk of retinopathy in insulin-dependent diabetes mellitus","volume":"332","author":"Warram","year":"1995","journal-title":"N\u00a0Engl J Med"},{"issue":"14","key":"10.1016\/j.rdc.2019.07.001_bib4","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJM199309303291401","article-title":"The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus","volume":"329","author":"Nathan","year":"1993","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.rdc.2019.07.001_bib5","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1056\/NEJMoa1001288","article-title":"Effects of medical therapies on retinopathy progression in type 2 diabetes","volume":"363","author":"Chew","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"Suppl 1","key":"10.1016\/j.rdc.2019.07.001_bib6","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1681\/ASN.2004110965","article-title":"Treatment of high-risk patients with diabetes: motivation and teaching intervention: a randomized, prospective 8-year follow-up study","volume":"16","author":"Rachmani","year":"2005","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"9118","key":"10.1016\/j.rdc.2019.07.001_bib7","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/S0140-6736(98)04311-6","article-title":"Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group","volume":"351","author":"Hansson","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.rdc.2019.07.001_bib8","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.rdc.2005.09.005","article-title":"The definition and measurement of disease modification in inflammatory rheumatic diseases","volume":"32","author":"Aletaha","year":"2006","journal-title":"Rheum Dis Clin North Am"},{"issue":"6219","key":"10.1016\/j.rdc.2019.07.001_bib9","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1136\/bmj.280.6219.964-a","article-title":"Do drugs change the course of rheumatoid arthritis?","volume":"280","author":"Wright","year":"1980","journal-title":"Br Med J"},{"issue":"1","key":"10.1016\/j.rdc.2019.07.001_bib10","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0889-857X(21)00173-3","article-title":"Aggressive therapy does not substantially alter the long-term course of rheumatoid arthritis. So what else is new?","volume":"19","author":"Kushner","year":"1993","journal-title":"Rheum Dis Clin North Am"},{"issue":"Suppl 25","key":"10.1016\/j.rdc.2019.07.001_bib11","first-page":"4","article-title":"Challenging the therapeutic pyramid: a new look at treatment strategies for rheumatoid arthritis","volume":"17","author":"Wilske","year":"1990","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.rdc.2019.07.001_bib12","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/S0140-6736(89)92442-2","article-title":"Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis","volume":"1","author":"van der Heijde","year":"1989","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.rdc.2019.07.001_bib13","doi-asserted-by":"crossref","first-page":"699","DOI":"10.7326\/0003-4819-124-8-199604150-00001","article-title":"The effectiveness of early treatment with \"second-line\" antirheumatic drugs. A randomized, controlled trial","volume":"124","author":"van der Heide","year":"1996","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.rdc.2019.07.001_bib14","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1136\/ard.2003.014928","article-title":"A\u00a0good response to early DMARD treatment of patients with rheumatoid arthritis in the first year predicts remission during follow up","volume":"64","author":"Verstappen","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2019.07.001_bib15","article-title":"Infliximab consistently induces clinical remission in patients with early active rheumatoid arthritis regardless of remission criteria","author":"Smolen","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.rdc.2019.07.001_bib16","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1002\/art.24433","article-title":"Rheumatoid arthritis joint progression in sustained remission is determined by disease activity levels preceding the period of radiographic assessment","volume":"60","author":"Aletaha","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.rdc.2019.07.001_bib17","doi-asserted-by":"crossref","first-page":"406","DOI":"10.7326\/0003-4819-146-6-200703200-00005","article-title":"Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial","volume":"146","author":"Goekoop-Ruiterman","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.rdc.2019.07.001_bib18","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0140-6736(04)16676-2","article-title":"Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial","volume":"364","author":"Grigor","year":"2004","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.rdc.2019.07.001_bib19","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1136\/ard.2007.071092","article-title":"Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial)","volume":"66","author":"Verstappen","year":"2007","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.rdc.2019.07.001_bib20","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1136\/ard.2010.141234","article-title":"The impact of four dynamic, goal-steered treatment strategies on the 5-year outcomes of rheumatoid arthritis patients in the BeSt study","volume":"70","author":"Klarenbeek","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.rdc.2019.07.001_bib21","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1093\/rheumatology\/31.8.519","article-title":"Prognostic factors for radiographic damage and physical disability in early rheumatoid arthritis. A prospective follow-up study of 147 patients","volume":"31","author":"Van der Heijde","year":"1992","journal-title":"Br J Rheumatol"},{"issue":"3","key":"10.1016\/j.rdc.2019.07.001_bib22","first-page":"425","article-title":"Interrelationship of outcome measures and process variables in early rheumatoid arthritis. A comparison of radiologic damage, physical disability, joint counts, and acute phase reactants","volume":"21","author":"van Leeuwen","year":"1994","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.rdc.2019.07.001_bib23","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1002\/art.21678","article-title":"Predictors of joint damage in\u00a0patients with early rheumatoid arthritis treated with high-dose methotrexate without or with concomitant infliximab. Results from the ASPIRE trial","volume":"54","author":"Smolen","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2019.07.001_bib24","first-page":"561","article-title":"Criteria for clinically important changes in outcomes: development, scoring and evaluation of rheumatoid arthritis patients and trial profiles","volume":"20","author":"Goldsmith","year":"1993","journal-title":"J\u00a0Rheumatol"},{"issue":"11","key":"10.1016\/j.rdc.2019.07.001_bib25","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.3899\/jrheum.080182","article-title":"RAPID3 (Routine Assessment of Patient Index Data 3), a rheumatoid arthritis index without formal joint counts for routine care: proposed severity categories compared to disease activity score and clinical disease activity index categories","volume":"35","author":"Pincus","year":"2008","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.rdc.2019.07.001_bib26","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1002\/art.22052","article-title":"Measuring function in rheumatoid arthritis: identifying reversible and irreversible components","volume":"54","author":"Aletaha","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.rdc.2019.07.001_bib27","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1136\/ard.2009.123919","article-title":"Treating rheumatoid arthritis to target: recommendations of an international task force","volume":"69","author":"Smolen","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.rdc.2019.07.001_bib28","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1136\/ard.2011.149765","article-title":"American College of Rheumatology\/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials","volume":"70","author":"Felson","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.rdc.2019.07.001_bib29","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1136\/annrheumdis-2015-208324","article-title":"Optimisation of a treat-to-target approach in rheumatoid arthritis: strategies for the 3-month time point","volume":"75","author":"Aletaha","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.rdc.2019.07.001_bib30","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1136\/annrheumdis-2013-203419","article-title":"Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force","volume":"73","author":"Smolen","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.rdc.2019.07.001_bib31","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2017-211734","article-title":"Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force","volume":"77","author":"Smolen","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.rdc.2019.07.001_bib32","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/acr.20155","article-title":"Validation of minimal disease activity criteria for psoriatic arthritis using interventional trial data","volume":"62","author":"Coates","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"5","key":"10.1016\/j.rdc.2019.07.001_bib33","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1136\/annrheumdis-2015-207507","article-title":"Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score","volume":"75","author":"Schoels","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.rdc.2019.07.001_bib34","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1136\/annrheumdis-2016-209511","article-title":"Disease activity states of the DAPSA, a psoriatic arthritis specific instrument, are valid against functional status and structural progression","volume":"76","author":"Aletaha","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.rdc.2019.07.001_bib35","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1136\/annrheumdis-2015-207526","article-title":"Evidence for treating rheumatoid arthritis to target: results of a systematic literature search update","volume":"75","author":"Stoffer","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.rdc.2019.07.001_bib36","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1136\/ard.2009.123976","article-title":"Evidence for treating rheumatoid arthritis to target: results of a systematic literature search","volume":"69","author":"Schoels","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2019.07.001_bib37","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1136\/annrheumdis-2013-203860","article-title":"Treating axial and peripheral spondyloarthritis, including psoriatic arthritis, to target: results of a systematic literature search to support a consensus statement","volume":"73","author":"Schoels","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"10012","key":"10.1016\/j.rdc.2019.07.001_bib38","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1016\/S0140-6736(15)00347-5","article-title":"Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial","volume":"386","author":"Coates","year":"2015","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.rdc.2019.07.001_bib39","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1136\/annrheumdis-2016-209467","article-title":"Treat-to-target (T2T) recommendations for gout","volume":"76","author":"Kiltz","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.rdc.2019.07.001_bib40","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1136\/annrheumdis-2013-205139","article-title":"Treat-to-target in systemic lupus erythematosus: recommendations from an international task force","volume":"73","author":"van Vollenhoven","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.rdc.2019.07.001_bib41","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2015-207524","article-title":"Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force","volume":"75","author":"Smolen","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.rdc.2019.07.001_bib42","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1002\/art.40111","article-title":"Implementation of treat-to-target in rheumatoid arthritis through a learning collaborative: results of a randomized controlled trial","volume":"69","author":"Solomon","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"10","key":"10.1016\/j.rdc.2019.07.001_bib43","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1002\/acr.23508","article-title":"Benefits and sustainability of a learning collaborative for implementation of treat-to-target in rheumatoid arthritis: results of a cluster-randomized controlled phase II clinical trial","volume":"70","author":"Solomon","year":"2018","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"3","key":"10.1016\/j.rdc.2019.07.001_bib44","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/j.1755-5922.2011.00308.x","article-title":"Effect of tight blood glucose control versus conventional control in patients with type 2 diabetes mellitus: a systematic review with meta-analysis of randomized controlled trials","volume":"31","author":"Buehler","year":"2013","journal-title":"Cardiovasc Ther"},{"issue":"2","key":"10.1016\/j.rdc.2019.07.001_bib45","doi-asserted-by":"crossref","first-page":"R46","DOI":"10.1186\/ar1902","article-title":"Methotrexate in rheumatoid arthritis is frequently effective, even if re-employed after a previous failure","volume":"8","author":"Kapral","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.rdc.2019.07.001_bib46","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update","volume":"76","author":"Smolen","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.rdc.2019.07.001_bib47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/acr.22783","article-title":"2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis","volume":"68","author":"Singh","year":"2016","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"7","key":"10.1016\/j.rdc.2019.07.001_bib48","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1111\/1756-185X.12754","article-title":"APLAR rheumatoid arthritis treatment recommendations","volume":"18","author":"Lau","year":"2015","journal-title":"Int J Rheum Dis"},{"issue":"3","key":"10.1016\/j.rdc.2019.07.001_bib49","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1136\/annrheumdis-2015-208337","article-title":"European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update","volume":"75","author":"Gossec","year":"2016","journal-title":"Ann Rheum Dis"}],"container-title":["Rheumatic Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X19300559?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X19300559?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T11:16:49Z","timestamp":1760181409000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889857X19300559"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":49,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["S0889857X19300559"],"URL":"https:\/\/doi.org\/10.1016\/j.rdc.2019.07.001","relation":{},"ISSN":["0889-857X"],"issn-type":[{"value":"0889-857X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treat to Target in Rheumatology","name":"articletitle","label":"Article Title"},{"value":"Rheumatic Disease Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rdc.2019.07.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}